PCI Outshines Drug Therapy In Study Of Post-Heart-Attack Silent Ischemia
This article was originally published in The Gray Sheet
Executive Summary
Percutaneous intervention offers long-term advantages to drug therapy in recent heart attack patients who continue to have damaging coronary artery blockage but do not experience chest pain, according to a study published in the May 9 Journal of the American Medical Association.
You may also be interested in...
COURAGE Suggests Stents Do Not Benefit Stable Coronary Disease Patients
Results of the highly anticipated COURAGE trial challenge the widespread assumption that stents improve outcomes in patients with stable coronary disease, but several observers believe the findings' impact on the stent market will be modest
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.